Breast cancer metastasis to bone represents a devastating complication of advanced breast cancer, frequently resulting in significant increases in morbidity and mortality. An understanding of the mechanisms that govern breast cancer metastasis at the molecular level should lead to more effective therapies. Recently, the kringle 1 domain of human hepatocyte growth factor (HGFK1) was identified as a candidate metastasis suppressor gene. Here, we investigated whether HGFK1 is a key regulator of breast cancer bone metastasis. Of the 193 human breast carcinoma tissue samples examined, HGFK1 expression was relative higher in 82 (42.4%) by western blot and in 84 (43.5%) by quantitative real-time PCR. The higher expression of HGFK1 was significantly associated with a better prognostic value (Po0.001) and inversely correlated with bone metastasis (P ¼ 0.003). The efficacy of adeno-associated virus carrying HGFK1 (AAV-HGFK1) in osteolytic bone metastasis was then evaluated using an in vivo bone metastasis model. AAV-HGFK1 significantly inhibited osteolytic bone metastasis and prolonged the survival of mice in this model (Po0.01). In vitro, HGFK1 expression resulted in significant anti-invasion effects, enhanced the phosphorylation of TAK1 (transforming growth factor-b-activated kinase 1), p38 MAPK (mitogen-activated protein kinase) and MAPKAPK2 (MAPK-activated protein kinase 2) and decreased the expression of receptor activator of nuclear factor-kB (RANK), which was abrogated by the p38 MAPK inhibitor SB203580. This study shows for the first time that HGFK1 significantly inhibits the metastasis of breast cancer to bone by activating the TAK1/p38 MAPK signaling pathway and inhibiting RANK expression. Thus, AAV-HGFK1 treatment represents a potential therapy for bone metastasis in breast cancer.
INTRODUCTION
Breast cancer is the most common form of malignancy in women, with an incidence of 1 in 39 individuals worldwide, and is the second leading cause of cancer death in women after lung cancer. 1 The metastasis of breast cancer to bone occurs in 480% of patients with advanced disease, causing morbidity, severe intractable bone pain, susceptibility to fractures, hypercalcemia and nerve compression syndrome, and resulting in a significant decline in the quality of life. 2 Although significant progress has been made in the treatment of breast cancers, bone disseminated breast cancer is still a devastating complication of malignancy. Most of the evidence in the literature suggests that the primary mechanism for bone destruction is the stimulation of osteoclastic bone resorption. 3 The binding of receptor activator of nuclear factor-kB ligand (RANKL) to RANK on preosteoclasts or osteoclasts is essential for the maturation and activity of these cells. 4--7 The decoy receptor of RANKL (osteoprotegerin (OPG)) prevents binding of RANKL to RANK and thus inhibits osteoclast activity and bone metastasis. 8, 9 The kringle 1 domain of human hepatocyte growth factor (HGFK1) includes amino-acid residues 127--214 of HGF, with a molecular mass of B11 kDa. Previous studies have shown that HGFK1 inhibits cell proliferation stimulated by basic fibroblast growth factors and causes cell apoptosis. 10 However, much remains to be learned about the contribution of HGFK1 to cancer, especially to breast cancer bone metastasis. We previously showed that HGFK1 exerts both antiangiogenic and antitumor activities in hepatocellular carcinoma through the epidermal growth factor (EGF)/epidermal growth factor receptor (EGFR) signaling pathway. 11 A recent report demonstrated that EGF-like ligands have the ability to strongly stimulate osteoclastogenesis in an EGFR-dependent manner. 12 Based on these findings, we wondered if HGFK1 might be a key regulator during the process of breast cancer metastasis to bone and osteoclastogenesis.
Among the new lines of therapies for breast cancer bone metastasis, gene therapy appears to be highly promising. As the pathology of osteolytic bone damage in breast cancer affects multiple regions of the skeleton, genetic therapies aimed at controlling this process should be sustained and systemic. We employed a recombinant adeno-associated viral (AAV) vector, a nonpathogenic vector that causes no known disease in humans. We have previously demonstrated the potentiality of AAV encoding antiangiogenic factors for long-term tumor-free survival with no vector-associated pathogenicity or toxicity. 11 In this study, we constructed an AAV encoding HGFK1 (AAV-HGFK1) and demonstrated the effects of administration of AAV-HGFK1 in treating osteolytic bone damage in a mouse model of bone metastasis. In addition, the effect of AAV-HGFK1 and the mechanism were observed in human breast cancer cell line MDA-MB-231-BO, which is derived from osseous metastases.
PATIENTS AND METHODS Patients
Tumor specimens from 193 patients who underwent surgery for primary breast cancer from 2002 to 2005 at the Cancer Center at the Hospital of Qingdao University and Shanghai Cancer Hospital, China, were evaluated in this study. The samples were used with the written informed consent of the patient and the approval of the ethic committee of the Hospital of Qingdao University and Shanghai Cancer Hospital. The basic demographics of this group and the pathological characteristics are shown in Tables 1 and 2 , respectively. A computerized database containing updated clinicopathological information was available for statistical analysis.
Western blot
For western blot analysis, samples were homogenized in a buffer (pH 7.9) containing 10 mM HEPES, 10 mM KCl, 1.5 mM MgCl 2 , 0.5 mM DTT, 0.5 mM PMSF, 10 mg ml À1 aprotinin and 10 mg ml À1 leupeptin. Total protein is 100 mg ml À1 . The resulting protein extracts were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane. The membrane was incubated with primary and secondary antibodies (1 h each) at B25 1C. Signals were developed using an Enhanced Chemiluminescence (ECL) kit (Amersham Pharmacia Biotech, Buckinghamshire, UK).
Quantitative real-time PCR analysis
The following primers were designed using the Beacon Designer 6 software (PREMIER Biosoft International, Palo Alto, CA, USA) and synthesized (with cartridge purification) by STAB Vida (Lisbon, Portugal): 0 . Quantitative real-time PCR analysis were performed on iQ 96-well PCR plates covered with Optical Sealing Tape (Bio-Rad, Hercules, CA, USA). Reactions were manually assembled and contained 0.25 mM of each primer, 10 ml of iQ SYBR Green Supermix (Bio-Rad) and 2 ml of template complementary DNA cDNA; dilution 1/9). The data obtained were analyzed using the iQ5 Optical System Software v2.1 (Bio-Rad). Efficiency values were calculated and the Cq values for each data set were exported to a Microsoft Office Excel file, and imported into the qbase PLUS2 software (Biogazelle, Zwijnaarde, Belgium). The relative quantities of each sample were calculated using the gene-specific efficiency acquired from the dilutions series and normalized to the mean Cq value.
Cell line, animals and reagents A highly bone metastatic clone of the human breast cancer cell line MDA-MB-231-BO was kindly provided by Professor Zhi-min Shao (Fudan University Shanghai Cancer Center, Shanghai, China) and maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum.
Female athymic BALB/c mice, 6 weeks old, were purchased from the Chinese Academy of Science, Shanghai Branch, and maintenance of the animals was carried out following guidelines of the institutional animal care and use committee of the Affiliated 6th People's Hospital, Shanghai Jiaotong University.
A tartrate-resistant acid phosphatase (TRAP) kit was purchased from Sigma-Aldrich (St Louis, MO). Anti-human HGFK1 polyclonal antibodies were produced by injection of the NH 2 -terminal peptide of HGFK1 (RSY KGT VSI TKS GIKC) into a rabbit. Other antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). SB203580 was purchased from Calbiochem-Novabiochem Corp. (San Diego, CA, USA).
Construction of recombinant AAV
The plasmids pAAV-CAG-sec-enhanced-EGFP and pAAV-CAG-sec-HGFK1 were constructed by inserting fragments encoding the EGFP and human HGFK1 cDNAs into the multiple cloning site of the AAV2 vector (ITR-CAG promoter-Igk leader-EGFP/HGFK1 cDNA-WPRE-BGH polyA-ITR). A helper virus-free system was used to produce the AAV-HGFK1 or AAV-EGFP particles, as described elsewhere, 13 but with minor modifications. Briefly, the AAV vectors and the pDG helper plasmid were co-transfected into HEK 293-FT cells by calcium phosphate precipitation. At 60 h after transfection, cells were trypsinized and resuspended in Tris buffer (pH 8.0). After two cycles of freezing and thawing, the cells were centrifuged. The supernatant containing AAV-HGFK1 or AAV-EGFP particles was decanted and purified by HiTrap Heparin column chromatography (Sigma, St Louis, MO). Peak virus fractions were collected and dialyzed against phosphate-buffered saline (PBS) containing 1 mM MgSO 4 . Samples were then concentrated using a 100 K-MicroSep Centrifugal Concentrator (Life Technologies, Carlsbad, CA). The viral titer was quantified using the Taqman Universal PCR kit (Applied Biosystems, Foster City, CA, USA) and WPRE-specific primers (forward, 5 0 -CGGCTGTTGGGCACTGA-3 0 ; reverse, 5 0 -CCGAAGGGAC-GAAGCAGAAG-3 0 ). Aliquots of each viral stock (2 Â 10 12 vector genome ml À1 (vg ml À1 )) were stored at À80 1C before use.
Bone metastasis model of breast cancer
A total of 1 Â 10 6 MDA-MB-231-BO cells were injected intratibially into the left leg of each BALB/c nude mouse to establish a bone metastasis model of breast cancer. After 14 days, the mice were divided into three groups consisting of 12 animals each; among these, 6 animals in each group were kept for survival curve data. Injection of AAV-HGFK1 or AAV-EGFP was conducted intratumorally at three sites around the margin of tumor nodule, at one site in the center of the tumor nodule (total 0.5 Â 10 11 vg in a volume of 50 ml for the four sites), and through the portal vein (0.5 Â 10 11 vg per mouse in a volume of 50 ml) each week. An equal number of age-matched animals (n ¼ 6) treated with PBS alone were included as controls.
Radiographs and histomorphometry
At 3 weeks after the initiation of treatment, the tumor-bearing hind legs of the mice were assessed for osteolytic lesions by radiography (Kodak X-OMAT TL film, Eastman Kodak Co., Rochester, NY, USA) using a Hewlett Packard X-ray system Faxitron 43805 (Hewlett-Packard Co., Palo Alto, CA, USA) and photographed.
After the mice were killed, soft tissues were weighed and fixed with formalin before embedding in paraffin for histological analysis. Bone tissues were decalcified before they were embedding in paraffin. Longitudinal serial sections (6 mm) were cut from the femur and tibia and stained with hematoxylin and eosin. TRAP staining was performed on bone sections to determine osteoclast activity. Quantitative assessment of TRAPpositive osteoclasts was performed using an Olympus BX51 microscope (Olympus America Inc., Melville, NY, USA) and Bioquant Image Analysis Software (R&M Biometrics, Nashville, TN). The expression of RANK, RANKL and OPG in the tumor tissues derived from mice in the three groups was examined by western blot.
Transwell migration assay
The transwell migration assay was conducted as previously described. 14 Briefly, 2 Â 10 4 MDA-MB-231-BO cells that are treated with PBS, rAAV-EGFP or rAAV-HGFK1 for 6 h were suspended with 200 ml Dulbecco's modified Eagle's medium without fetal bovine serum and placed onto the upper chamber. The lower chamber was filled with 500 ml Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. Cells were allowed to migrate through Polycarbonate Membranes (8.0 mm pore, Corning Costar, Cambridge, MA) at 37 1C in 5% CO 2 /95% air for 24 h. The cells remaining on the upper surface of the filter were removed, and those that migrated to the lower compartment were fixed with Methanol, stained with crystal violet and scored visually in five random fields under a microscope (using the Â 10 objective lens). In addition, invaded cells were dissociated, lysed and quantified at 570 nm using spectrophotometer.
Wound healing assay
The effect of AAV-HGFK1 on the cell migration was evaluated using a wound healing assay as previously described.
14 Briefly, 1 Â 10 6 MDA-MB-231-BO cells were plated in six-well plates and incubated overnight to reach 90% confluence. Then, the cells were scratched with a sterile 200-ml pipette tip to form straight wounds. Plates were then rinsed with PBS to remove floating cells and fed with 2 ml of media. PBS, rAAV-EGFP or rAAV-HGFK1 (multiplicity of infection, 1 Â 10 4 ) was administered for 6 h. The cells were observed under phase contrast microscope and photographed after 24 h of incubation. For each replicate (n ¼ 3), the numbers of cells in five randomly selected fields were determined, and the counts were averaged.
Statistical analysis
Animal survival was analyzed by log-rank test using the GraphPad Prism software (GraphPad Software, San Diego, CA, USA). The two-tailed Student's t-test application of MS Excel was used for all continuous outcome variables, such as tumor size and number of metastases. Repeated Student's t-test was used to compare the AAV-HGFK1-treated group with the control group with regard to tumor volumes across time from 0 to 21 days after treatment. The results are presented as mean ± s.e.m. and considered significantly different if the P-value was o0.05.
RESULTS
Prognostic value of HGFK1 in the tumor tissues of patients with primary breast cancer Fresh tumor samples from 193 patients with primary breast cancer were investigated using western blot. The status of HGFK1 expression is shown in Figure 1a . A total of 82 samples (42.4%) were HGFK1 positive (Table 2 ). HGFK1-positive status was associated with the Her-2 expression status (P ¼ 0.016), the status of lymph nodes (P ¼ 0.015), tumor size (P ¼ 0.005) metastases (P ¼ 0.028) and bone metastases (P ¼ 0.003), whereas it was not associated with estrogen receptor status (P ¼ 0.583), progesterone receptor status (P ¼ 0.184) or cell differentiation (P ¼ 0.248; Table 2 ).
Univariate analysis of HGFK1-positive status shows a significant association with a longer overall survival (Po0.001) and diseasefree survival (P ¼ 0.006) (Figure 1b) . In multivariate Cox proportional hazards analysis, HGFK1 expression was not an independent predictor of overall survival (P ¼ 0.638) and disease-free survival (P ¼ 0.451).
The results of quantitative real-time PCR analysis of HGFK1 gene expression in the same samples were consistent with that of western blot analysis (Figure 1c and Table 3 ).
AAV-HGFK1 inhibits tumor growth in bone and prolongs the survival of mice We previously demonstrated that expression of HGFK1 remained detectable at 120 days after administration of AAV-HGFK1 and did not observe any toxicity in vivo. In the present study, we mainly investigated whether AAV-HGFK1 could function as a suppressor of tumor growth in breast cancer bone metastasis in vivo. A total of 1 Â 10 11 vg of AAV-HGFK1 suspended in PBS was injected into the tumor of the hind limb and through the caudal vein at a volume of 50 ml every week. In addition, 1 Â 10 11 vg of AAV-EGFP or PBS was administered to mice with bone metastatic tumors as controls (n ¼ 6 for each condition).
At 3 weeks after treatment, the 18 mice were killed by cervical dislocation, and tumor tissues were isolated for assessment. The average tumor volumes of the mice in the PBS-treated and AAV-EGFP-treated groups were 3371.89 ± 539.67 and 3110.02 Figure 2a ). No significant difference was observed between the two control groups.
Additionally, the median survival time in the control (PBS and AAV-EGFP) groups were 44 and 41 days after treatment, respectively, whereas AAV-HGFK1 treatment significantly prolonged the median survival time to 70 days (Po0.01; Figure 2b ).
AAV-HGFK1 therapy has an inhibitory effect on osteolytic lesions
The X-ray images of tumor-bearing tibiae taken just before killing confirmed the presence of osteolysis in all animals. In the control groups, a characteristic 'osteolytic lesions' configuration was also evident, extending into the surrounding soft tissues. Relative to the control groups, the AAV-HGFK1-treated tumor lesion size was greatly reduced. Cross-sections of the X-ray images of the tumorbearing tibiae of the control groups revealed significant cortical bone destruction and loss of trabecular architecture. In contrast, the AAV-HGFK1-treated tumor-bearing tibiae displayed smoother cortical bone surfaces and fewer lesions than the control groups (Figure 3a) .
Histomorphometry of the tibia was also performed. The hematoxylin and eosin staining results indicated that in PBStreated mice or AAV-EGFP-treated mice, tumor cells replaced the bone marrow completely, and prominent bone damage was noticed in both the trabecular and cortical bone areas at 3 weeks after intratibial injection of MDA-MB-231-BO cells (Figure 3b ). The majority of the tumor cells were present in the metaphyseal region, which also displayed maximum bone destruction. In the diaphyses, tumor cells invaded into the calcified cortex and were found to grow in small pockets initially and eventually produced complete bone destruction. In contrast, in AAV-HGFK1-treated mice, the cortical and trabecular bone appeared normal, the metaphysis region of the tibia was almost devoid of any tumor cells, which were instead replaced by newly formed or trabecular bone. Hematoxylin and eosin staining of the bone sections showed a remarkable decrease in tumor burden and bone osteolysis in AAV-HGFK1-treated mice compared with the control mice.
TRAP staining was performed to identify osteoclasts present in the bone lesions of the mice. In AAV-HGFK1-treated mice, the number of osteoclasts is much lower than that in the control mice (Figure 3c ). In PBS-treated mice or AAV-EGFP-treated mice, the osteoclasts were located along the entire tumor/bone interface, including both the metaphyseal and the diaphyses. However, in AAV-HGFK1-treated mice, osteoclasts were primarily located in the metaphysis of the tibia and were significantly fewer than in the controls.
Osteolysis is mainly regulated by the RANK/RANKL/OPG system. We observed the expression of RANK, RANKL and OPG in the tumor tissues of each of the treatment groups by western blot. Our results show that RANK expression is downregulated in the AAV-HGFK1 treatment group, whereas the expression levels of RANKL and OPG did not differ between the AAV-HGFK1 treatment group and the control groups (Figure 4 ). AAV-HGFK1 reduces the invasive potential of MDA-MB-231-BO cells MDA-MB-231-BO cells infected with AAV-HGFK1 showed HGFK1 expression as evidenced by western blot analysis, whereas the AAV-EGFP and mock-infected groups did not show measurable HGFK1 expression (Figure 5a) .
Cell migration is a critical metastatic event that occurs in various epithelial cells during cancer progression. We next examined whether AAV-HGFK1 is able to prevent the migration of MDA-MB-231-BO cells. We tested the effects of AAV-HGFK1 on migration AAV-HGFK1 exhibits an anti-invasion effect on MDA-MB-231-BO cells mainly through the p38 MAPK signaling pathway To identify the mechanisms responsible for HGFK1 overexpression-induced inhibition of cell migration, we next measured the levels of phosphorylated p38 mitogen-activated protein kinase (MAPK), a key factor in cell migration, in MDA-MB-231-BO cells by western blotting. When exposed to AAV-HGFK1, the phosphorylation of various proteins in the p38 MAPK cascade, including transforming growth factor-b-activated kinase 1 (TAK1), p38 MAPK and MAPKAPK2 (mitogen-activated protein kinase-activated protein kinase 2), was increased; however, this increase was specifically abrogated by inhibition of p38 MAPK using SB203580 (40 mM). Thus, the effect of HGFK1 overexpression in MDA-MB-231-BO cells on metastasis may be mediated by the activation of the TAK1/p38 MAPK signaling pathway. In addition, AAV-HGFK1 treatment inhibited the expression of RANK in MDA-MB-231-BO cells, and this inhibitory effect was abolished by the p38 MAPK inhibitor SB203580 (Figure 6a) .
Additionally, we found that inhibition of p38 MAPK using SB203580 reversed the anti-migration effect of AAV-HGFK1 on MDA-MB-231-BO cells using a wound healing assay (Figure 6b ).
DISCUSSION
Bone metastasis is one of the most grave events in the progression of breast cancer. 2 Researchers have made many efforts to cure the bone metastasis of cancers. The most promising novel treatments include denosumab, a monoclonal antibody against RANKL; odanacatib, a specific inhibitor of the osteoclast protease cathepsin K; and antibodies against the proteins sclerostin and dickkopf-1, the two endogenous inhibitors of bone formation. 15 Nevertheless, an effective cure for bone metastasis of cancers remains out of reach.
In this study, we observed that HGFK1 expression was associated with the metastasis of breast cancer to bone and showed the prognostic value of HGFK1 expression in patients with Figure 3 . Effect of AAV-HGFK1 (adeno-associated virus carrying kringle 1 domain of human hepatocyte growth factor) treatment on breast cancer-induced bone destruction assessed by X-rays, hematoxylin and eosin (H&E) and tartrate-resistant acid phosphatase (TRAP) stain in vivo.
(a) Radiographs showing a tumor that broke through the bone cortex of tibia in control animals, whereas almost no bone destruction was found in the AAV-HGFK1-treated animals (yellow circles). (b; H&E staining, 2 Â 10 magnification) Large areas of the tibia were destroyed and invaded by breast cancer cells in control mice, whereas much less osteolysis and breast cancer tumor was found in the tibia of AAV-HGFK1-treated animals (yellow circles). (c) Tissue sections around the tibia were also stained for TRAP activity to determine the presence of mature osteoclasts (stained in deep blue), which was considered an index of osteolysis. Osteoclast numbers in the AAV-HGFK1 treatment group were much fewer than those of the control groups. AAV-EGFP: treated with the AAV-EGFP virus vector as a control; AAV-HGFK1: treated with the AAV-HGFK1 expression vector; Mock: treated with phosphate-buffered saline (PBS) as negative control. breast cancer. Our results show that HGFK1 expression is correlated with longer survival of patients with breast cancer (overall survival, Po0.001; disease-free survival, P ¼ 0.006) and fewer bone metastases (P ¼ 0.003). These data suggest that HGFK1 might contribute to future treatments of bone metastasis of breast cancer (Figure 1) .
A suitable animal model of bone metastasis of breast cancer was needed to investigate the in vivo therapeutic efficacy of HGFK1. One of the most widely used models is nude mice with bone lesions induced by intratibial injections of cancer cells. 16 However, this model does not represent all the attributes of clinical metastasis. A fully metastatic model is needed in a future study. In this study, the MDA-MB-231-BO cell line derived from osseous metastases was chosen to inoculate into the tibiae of BALB/c female mice to establish an animal model of breast cancer metastasis to bone. AAV was chosen to deliver HGFK1 gene into the tumor because of its long-sustained expression of target genes with no vector-associated pathogenicity or toxicity. 17, 18 This might be crucial in a clinical setting, and, in particular, in cancer gene therapy, where prolonged expression of the therapeutic gene might be required to achieve a long-term outcome. Our in vivo results clearly demonstrate that moderate doses of AAV-HGFK1 (1 Â 10 11 vg) can significantly reduce the tumor growth and the osteolytic lesions in bone (Figure 2a) . Furthermore, AAV-HGFK1 significantly prolongs the survival time of animals with breast cancer bone metastases (Figure 2b ). Detailed analysis of the bone architecture by histomorphometry and X-ray indicated that the systemically stable HGFK1 gene therapy decreases osteoclastogenesis and promotes new bone formation. The prevention of bone loss also resulted in a significantly lowered tumor burden in the bone (Figures 3a and b) . The vicious cycle hypothesis of tumor-induced bone breakdown suggests that cancer-induced bone metastasis results from the inter-influence of cancer cells and bone marrow. The TRAP staining further determined that bone destruction in AAV-HGFK1-treated mice is reduced relative to the control groups (Figure 3c ). RANKL and its receptor RANK have been shown to be key factors in stimulating osteoclast formation. We found that tumor cells exposed to AAV-HGFK1 had decreased expression of RANK (Figure 4) . In concordance, AAV-HGFK1 was able to block osteoclast maturation and function and prevent bone loss in mice.
We previously demonstrated that HGFK1 exerts its antiangiogenic and antitumor effects by inhibiting the EGF/EGFR signaling pathway. 11 Recently, some researchers demonstrated that EGF-like ligands have the ability to strongly stimulate osteoclastogenesis in an EGFR-dependent manner. 12 We wondered if HGFK1 might be a key regulator during the process of breast cancer metastasis to bone and osteoclastogenesis. In this study, we also observed an anti-invasion effect of AAV-HGFK1 on the breast cancer cell line MDA-MB-231-BO using a transwell assay ( Figure 5 ). Next, we sought to establish which molecular mechanisms are responsible for the inhibition of invasion, which would facilitate development of strategies to control metastasis. Importantly, transforming growth factor-b plays a pivotal role in regulating the metastasis of aggressive breast cancer cells. 19, 20 We then turned to the transforming growth factor-b-controlled p38 MAPK kinase pathway. In particular, previous findings establish that p38 MAPK signaling cascades are essential for tumor invasion and metastasis. 21 Therefore, we examined the functional significance of p38 MAPK activation in response to HGFK1. As measured by western blot, the phosphorylation of TAK1, p38 MAPK and MAPKAPK2 was induced in HGFK1-overexpressing cells and subsequently abrogated when we used a p38 MAPK inhibitor (SB203580) to block the p38 MAPK cascade. Importantly, this effect of HGFK1 expression on the suppression of MDA-MB-231-BO cell migration was abrogated by blocking the p38 MAPK cascade. Moreover, the downregulation of RANK, the expression of which associates with accelerated bone metastasis, 22 was reversed in the presence of p38 MAPK inhibitor ( Figure 6 ). Collectively, these data indicate that HGFK1 inhibits bone metastasis in breast cancer via TAK1/p38 MAPK signaling.
Overall, our study shows that AAV-HGFK1 significantly inhibits tumor growth and the osteolytic lesions in bone and prolongs the survival of mice with breast cancer bone metastasis. Sustained expression of HGFK1 suppressed invasion of MDA-MB-231-BO cells. These anti-invasion effects were associated with activation of TAK1/p38 MAPK signaling pathway and inhibition of RANK expression. AAV-HGFK1 may represent a novel therapeutic strategy for the repression of local and bone metastatic growth of human breast cancer.
